Shamburg News · 8-K filed Oct 14, 2026, 8:10 AM EDT

MaxCyte Reports Preliminary Q3 2026 Revenue and Raises 2026 Revenue Guidance

MXCT · MAXCYTE, INC.

  • Earnings
  • Materiality: high

On October 14, 2026, MaxCyte, Inc. reported preliminary, unaudited core business revenue of approximately $8.1 million for the third quarter ended September 30, 2026, up 26% from the prior year, plus more than $1.0 million of SPL Program-related revenue. The company raised full-year 2026 revenue guidance to approximately $34 million from $30 million to $32 million, including core business revenue of approximately $28 million from $25 million to $27 million. MaxCyte will report full third quarter results on November 10, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001104659-26-115745.

Written from the filing by Shamburg Markets. Figures are as reported by the company.